Skip to content
Black Week: 20% off everything, code BLACK

Search

What are you looking for?

Type at least 2 characters to see suggestions.

Semax 50 mg
Semax 50 mg
Semax 50 mg

Semax 50 mg

Semax 50 mg is a native heptapeptide MEHFPGP – an analogue of the ACTH(4-7) fragment extended with Pro-Gly-Pro, a reference form of the family in the form of a lyophilisate in a vial for reconstitution with bacteriostatic water (Endogenic line). Research Use Only reagent.

47,99 €
With code BLACK: 38,39 € Lowest price in the 30 days before the discount: 47,99 €

Product unavailable

Notify me when it is back

Leave your e-mail and we will send you one message when the product is available again.

View the laboratory analysis report

Semax 50 mg - research reagent in a vial

  • Semax 50 mg is a native heptapeptide MEHFPGP - an analogue of the ACTH(4-7) fragment extended with Pro-Gly-Pro, a reference form of the family in the form of a lyophilisate in a vial for reconstitution with bacteriostatic water (Endogenic line).
  • Research Use Only reagent.

Product status information

Chemical reagent intended exclusively for laboratory tests (Research Use Only). It is not a medicinal product, dietary supplement or food. It is not intended for use on humans or animals. Sales only to registered research units and laboratories.

Semax is the heptapeptide Met-Glu-His-Phe-Pro-Gly-Pro (MEHFPGP) – a native, unmodified form of the compound from the line Endogenous, developed in the 1980s as a synthetic analogue of the ACTH(4-7) fragment extended with the C-terminal tripeptide Pro-Gly-Pro. This is the molecule from which the entire family descends peptides on brain function tested for neurotrophin induction: the pharmacophore core responsible for the nootropic and neuroprotective profile in preclinical models remains in its initial form, with free chain ends.

However, the free N-terminus has its price. Native Semax disappears from the bloodstream within a few minutes – the half-life of the heptapeptide is counted in minutes, not hours, because the free α-amino group of methionine at the N-terminus becomes the target of aminopeptidases before the molecule has time to fully act. This is a known feature of short regulatory peptides and the reason why stabilized forms such as N-acetyl Semax 50mg.

Native Semax, however, remains the reference starting point: its pharmacological profile is described in most of the literature, and all modifications are compared to it. Semax is delivered as lyophilisate in a 50 mg vial — powder form, which the researcher reconstitutes himself with bacteriostatic water according to the parameters of the planned experiment. The vial format is a standard starting point in preclinical protocols for neuroprotective peptides – it gives full control over the concentration and volume of the working solution and remains stable for months in the freezer. Purity verified by HPLC ≥98%, identity confirmed by mass spectrometry, COA available for each batch.

Regulatory status

Semax is registered as a medicinal product in the Russian Federation — as a nootropic and neuroprotectant in the form of nasal drops, in indications including ischemic stroke, encephalopathy and optic neuropathy. It is not registered as a drug in the EU or the USA. As a research reagent, it remains in the Research Use Only category. Communicating the product as an “over-the-counter nootropic”, “peptide by heart” or “neuroprotector for biohackers” is contrary to the Research Use Only framework.

Semax, ACTH fragment and the Russian school of neuroprotective peptides

To understand Semax, you need to go back to the adrenocorticotropic hormone. ACTH is a 39-amino-acid pituitary peptide that stimulates the adrenal cortex to secrete cortisol – its classic hormonal function in the periphery. Already in the 1960s and 1970s, research showed that short fragments of the ACTH molecule, deprived of the part responsible for corticotropic activity, retain a clear effect on the central nervous system – on learning, memory and resistance to stress.

This opened up a separate direction: designing synthetic ACTH fragments as neuropeptides acting in the brain without an adrenal effect. In the 1980s, Ivan Ashmarin’s team at the Institute of Molecular Genetics of the Russian Academy of Sciences in Moscow took a fragment of ACTH(4-7) — the Met-Glu-His-Phe sequence — and added the C-terminal tripeptide Pro-Gly-Pro to it.

The heptapeptide Met-Glu-His-Phe-Pro-Gly-Pro was created, called Semax. The addition of proline tripeptide solved a specific problem: it protected the core from immediate degradation and at the same time enhanced the nootropic and neuroprotective profile in behavioral models. Semax was included in research on acute cerebral ischemia and cognitive disorders, and in the Russian Federation it was registered as a drug in the form of nasal drops – first in a lower concentration as a nootropic, later in a higher concentration as a neuroprotector in ischemic stroke.

Semax is a textbook example of the Russian school of regulatory peptides: a short sequence designed to separate neurotrophic activity from the hormonal action of the parent molecule. This is the native form of the core to which all subsequent analog work refers. Stabilized derivatives—such as N-acetyl Semax, in which the N-terminal α-amino group has been blocked with acetyl—modify the pharmacokinetics but inherit the mechanistic core of native Semax. For this reason, Semax remains the reference reagent for characterizing the profile of the entire family.

What is Semax?

Semax is a synthetic heptapeptide – an analogue of the ACTH(4-7) fragment (Met-Glu-His-Phe) extended with the C-terminal tripeptide Pro-Gly-Pro. Unlike acetylated forms, it has free chain ends, which is responsible for its short half-life.

  • Chemical name: Semax, native Semax
  • Sequence: Met-Glu-His-Phe-Pro-Gly-Pro (single letter: MEHFPGP)
  • Structural origin: an analogue of the ACTH(4-7) fragment (Met-Glu-His-Phe) extended with the C-terminal tripeptide Pro-Gly-Pro; native, unmodified form
  • Chemical class: neuroprotective/nootropic heptapeptide; melanocortin fragment of ACTH without corticotropic activity
  • Delivered form: lyophilisate (powder) in a vial, 50 mg of peptide per vial, for reconstitution with bacteriostatic water; pharmaceutical grade ≥98% HPLC

Table of physicochemical characteristics

Parameter Value Attention
Sequence MEHFPGP heptapeptide, native form (free ends)
CAS number 80714-61-0 native Semax
Summary formula C₃₇H₅₁N₉O₁₀S single methionine residue (sulfur)
Molar mass 813.92 g/mol monoisotopic mass verified by MS per batch
Isoelectric point moderately sour the presence of glutamate and histidine residues; free α-amino group of the N-terminus
Character white to off-white lyophilisate freeze-dried powder in a vial
Peptide content 50 mg/vial before reconstitution
Cleanliness ≥98% HPLC UV detection, per batch verification
Solubility good in the water reconstitution with bacteriostatic water

Mechanism of action at the molecular level

Semax works through several parallel neurobiological pathways. The following mechanisms have been documented for native Semax in preclinical models. Pharmacological profile described for Semax in research models:

  1. Induction of BDNF and NGF expression in the hippocampus and cortex — the best described mechanism. Semax changes the expression of brain-derived neurotrophic factor (BDNF) and its receptor TrkB in the rat hippocampus: a single administration raised BDNF protein at most 1.4-fold and BDNF mRNA (exon III transcript) about threefold; the compound also affects nerve growth factor (NGF) (Dolotov et al. 2006). This is likely the core of its nootropic and neuroprotective profile – increased availability of neurotrophins promotes synaptic plasticity and neuronal survival under conditions of metabolic stress.
  2. ACTH(4-7) analogue without corticotropic activity — Semax is derived from a fragment of ACTH, but does not contain the part of the molecule responsible for stimulating the adrenal cortex. In models, it does not stimulate cortisol secretion (no corticotropic effect), maintaining the central melanocortin profile. This distinction is important: neurotrophic and neuroprotective activity is separated from the adrenal hormonal action of parent ACTH.
  3. Modulation of dopaminergic and serotonergic transmission — some studies indicate the effect of Semax on the dopamine and serotonin systems in brain structures, which in rodent models correlates with the nootropic and neuroprotective profile. The mechanism probably involves modulation of monoamine release and an effect on the expression of genes related to dopamine metabolism.
  4. Inhibition of enkephalinases — Semax inhibits the activity of enkephalin-degrading enzymes in serum and tissue, which increases the concentration of endogenous Met- and Leu-enkephalins and prolongs enkephalinergic signaling. This component is a likely contributor to the analgesic and anxiolytic profile observed in the models.
  5. Neuroprotection in models of cerebral ischemia — in models of acute ischemia (cerebral artery occlusion in rodents), Semax modulated apoptosis, oxidative stress and the expression of neuroinflammatory and neurotrophic response genes (Medvedeva et al. 2017). This direction was the basis for the registration of Semax as a neuroprotector in ischemic stroke in the Russian Federation.

Pharmacokinetics - why the free N-terminus matters

The defining feature of native Semax is its very short half-life – on the order of minutes. The free α-amino group of methionine at the N-terminus is responsible for this: aminopeptidases cut it off quickly, degrading the molecule before it can fully reach the target. This is a typical limitation of short regulatory peptides with unblocked chain ends and at the same time the reason why stabilized forms were created.

Acetylation of the N-terminus in the acetylated form removes this point of attack and extends proteolytic stability – native Semax, however, remains the reference form with the shortest kinetics. The oral bioavailability of the peptide is virtually zero – the gastrointestinal tract degrades regulatory peptides before they can be absorbed. Two routes of administration dominate in the literature on Semax: parenteral administration and intranasal (nose-to-brain transport, partially bypassing the blood-brain barrier).

The nasal route is of particular importance here: the registration of native Semax in the Russian Federation concerns the form of nasal drops – the short life of the molecule in the bloodstream makes direct transport to the nervous tissue particularly important. This route of administration is reflected in the reagent catalog Semax spray as a ready-made intranasal solution, while the lyophilized vial format provides the researcher with a solution of controlled concentration for any route of administration planned in the protocol.

Applications in scientific research

Semax in lyophilized format is used in research areas on peptide neurotrophin inducers and central neuroprotection:

  • Models of neuroprotection in cerebral ischemia — middle cerebral artery occlusion (MCAO) in rodents; assessment of the effect on infarct size, neuronal apoptosis, oxidative stress and neurotrophic gene expression under acute ischemia.
  • BDNF, NGF and TrkB expression — transcription and protein studies in the cortex and hippocampus; characterization of the kinetics and strength of neurotrophin induction by native Semax and comparison with stabilized forms.
  • Cognitive models — memory and learning tests (Morris water maze, passive avoidance, new object recognition), especially in conditions of impaired cognitive function due to stress or hypoxia.
  • Neuroinflammatory models and responses to oxidative stress — assessment of the impact on the cytokine profile and oxidative stress markers in nervous tissue.
  • Melanocortin pharmacology of ACTH fragments — examination of the central activity of the ACTH(4-7) fragment separately from corticotropic activity; profile characterization without adrenal effect.
  • Pharmacokinetic characterization of the native form — reference assessment of the proteolytic stability and degradation profile of the free N-terminus as a reference point for stabilized analogues.
  • Monomaminergic models — influence on dopaminergic and serotonergic transmission and the expression of genes related to monoamine metabolism.
  • Enkephalinergic models — assessment of enkephalinase inhibition and the effect on the level of endogenous enkephalins in serum and tissue.

Summary

Semax is a native MEHFPGP heptapeptide – an analogue of the ACTH(4-7) fragment extended with the C-terminal tripeptide Pro-Gly-Pro, in an unmodified form with free chain ends. Supplied as a lyophilized product in a 50 mg vial for reconstitution with bacteriostatic water, Endogenic line. It is the reference form of the entire family – most of the mechanistic literature refers to it and stabilized forms such as N-acetyl Semax are characterized against it.

The free N-terminus gives native Semax a very short half-life (minutes) – methionine is quickly cleaved by aminopeptidases. The pharmacological profile includes induction of BDNF and NGF in the hippocampus and cortex (in the rat hippocampus, BDNF protein rose at most 1.4-fold), a central melanocortin profile without corticotropic activity (does not stimulate the adrenal cortex), modulation of dopaminergic and serotonergic transmission, inhibition of enkephalinases, and neuroprotection in models of cerebral ischemia – all documented in rodent and in vitro models, mainly by groups Russian-speaking.

Regulatory status – Research Use Only off-label in the Russian Federation. A nootropic peptide from the same family, complementary in research on the stress and mood axis, is described in the card Selank 10mg (tuftsin analogue, GABA and BDNF axis). The broader context of the classification and mechanisms of this compound group is discussed in the review nootropic substances.

Bibliography

  1. Dolotov OV, Karpenko EA, Inozemtseva LS, Seredenina TS, Levitskaya NG, et al. (2006). Semax, an analogue of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus. PubMed
  2. Medvedeva EV, Dmitrieva VG, Limborska SA, Myasoedov NF, Dergunova LV (2017). Semax, an analogue of ACTH(4-7), regulates expression of immune response genes during ischemic brain injury in rats. PubMed
  3. Sudarkina OY, Filippenkov IB, Stavchansky VV, Denisova AE, Dmitrieva VG, et al. (2021). Brain protein expression profile confirms the protective effect of the ACTH(4-7)PGP peptide (Semax) in a rat model of cerebral ischemia-reperfusion. PubMed

Chemical reagent Research Use Only. Semax 50 mg (native heptapeptide MEHFPGP, Endogenic line) in the Pro-Body catalog is not a medicinal product, dietary supplement or food. It is not intended for administration to humans or animals outside a controlled experimental environment. Semax is registered as a medicine in the Russian Federation (nasal drops – nootropic and neuroprotector); in the EU and the USA it is not registered as a medicinal product and remains an RUO reagent.

The information in the description is of an educational and scientific nature and refers to results reported in preclinical literature (rodent models, in vitro) – it does not constitute medical advice or administration instructions.